Cargando…
Rush immunotherapy in two cats with atopic skin syndrome
CASE SERIES SUMMARY: Two cats with feline atopic skin syndrome (FASS) were included in this case series. They were diagnosed with FASS by a combination of history, physical examination and exclusion of other pruritic diseases. They underwent rush immunotherapy (RIT) after determination of offending...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221683/ https://www.ncbi.nlm.nih.gov/pubmed/34221441 http://dx.doi.org/10.1177/20551169211023327 |
_version_ | 1783711369486401536 |
---|---|
author | Jones, Selene Bloom, Paul |
author_facet | Jones, Selene Bloom, Paul |
author_sort | Jones, Selene |
collection | PubMed |
description | CASE SERIES SUMMARY: Two cats with feline atopic skin syndrome (FASS) were included in this case series. They were diagnosed with FASS by a combination of history, physical examination and exclusion of other pruritic diseases. They underwent rush immunotherapy (RIT) after determination of offending environmental allergens by either serum IgE or intradermal testing. Cats were premedicated with an antihistamine and hospitalized for the day to undergo the procedure and to ensure adequate observation. Allergen extracts were administered subcutaneously at increasing concentrations every 30 mins until the maintenance dose of 20,000 protein nitrogen units/ml was reached. Both cats successfully completed RIT without any adverse reactions and their clinical signs improved afterwards. RIT appears to be an alternative treatment option for cats with FASS. Larger studies are needed to more accurately assess the safety and long-term efficacy of RIT in the feline patient, as well as the incidence of adverse reactions and optimal premedication protocol. Further evaluation of the route of injections for RIT is also warranted. RELEVANCE AND NOVEL INFORMATION: RIT has been reported to be a safe treatment option in canine atopic dermatitis. Its use in FASS is limited to a pilot study of four cats. The purpose of this series was to describe two additional cats that underwent RIT using a different premedication protocol. |
format | Online Article Text |
id | pubmed-8221683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-82216832021-07-01 Rush immunotherapy in two cats with atopic skin syndrome Jones, Selene Bloom, Paul JFMS Open Rep Case Series CASE SERIES SUMMARY: Two cats with feline atopic skin syndrome (FASS) were included in this case series. They were diagnosed with FASS by a combination of history, physical examination and exclusion of other pruritic diseases. They underwent rush immunotherapy (RIT) after determination of offending environmental allergens by either serum IgE or intradermal testing. Cats were premedicated with an antihistamine and hospitalized for the day to undergo the procedure and to ensure adequate observation. Allergen extracts were administered subcutaneously at increasing concentrations every 30 mins until the maintenance dose of 20,000 protein nitrogen units/ml was reached. Both cats successfully completed RIT without any adverse reactions and their clinical signs improved afterwards. RIT appears to be an alternative treatment option for cats with FASS. Larger studies are needed to more accurately assess the safety and long-term efficacy of RIT in the feline patient, as well as the incidence of adverse reactions and optimal premedication protocol. Further evaluation of the route of injections for RIT is also warranted. RELEVANCE AND NOVEL INFORMATION: RIT has been reported to be a safe treatment option in canine atopic dermatitis. Its use in FASS is limited to a pilot study of four cats. The purpose of this series was to describe two additional cats that underwent RIT using a different premedication protocol. SAGE Publications 2021-06-21 /pmc/articles/PMC8221683/ /pubmed/34221441 http://dx.doi.org/10.1177/20551169211023327 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Series Jones, Selene Bloom, Paul Rush immunotherapy in two cats with atopic skin syndrome |
title | Rush immunotherapy in two cats with atopic skin syndrome |
title_full | Rush immunotherapy in two cats with atopic skin syndrome |
title_fullStr | Rush immunotherapy in two cats with atopic skin syndrome |
title_full_unstemmed | Rush immunotherapy in two cats with atopic skin syndrome |
title_short | Rush immunotherapy in two cats with atopic skin syndrome |
title_sort | rush immunotherapy in two cats with atopic skin syndrome |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221683/ https://www.ncbi.nlm.nih.gov/pubmed/34221441 http://dx.doi.org/10.1177/20551169211023327 |
work_keys_str_mv | AT jonesselene rushimmunotherapyintwocatswithatopicskinsyndrome AT bloompaul rushimmunotherapyintwocatswithatopicskinsyndrome |